News

Sometimes a company has a mixture of proven performance and upcoming catalysts that make the idea of buying it hand-over-fist practically irresistible. And that's exactly what Vertex Pharmaceuticals

Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings.

When it was clear a few years ago that

Small-cap stocks have been under pressure ever since the Federal Reserve started hiking interest rates in the first quarter of 2022. As a result, scores of companies in this category sport

The last few years have been a miserable time to own AT&T (NYSE: T) stock. Thanks largely to its dividend income, AT&T investors earned a total return of just 13% over the last five years, a span

Pfizer (NYSE: PFE) stock has been in the dumps this year. It is struggling due to declining demand for its COVID products. And it may take some years before its top line starts rising meaningfully

It's fair to say that Editas Medicine (NASDAQ: EDIT) is an ailing biotech. Over the past three years, its share price has fallen by 83% as it abandoned parts of its pipeline and laid off staff

If you're looking for a stock that has the potential to grow your investment to $1 million, a good move may be to invest in a strong business that's in a fast-growing industry. Gene therapy is an

Could the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a towering, innovative, and profitable growth business, as biopharma Vertex Pharmaceuticals (NASDAQ: VRTX)

Regeneron Pharmaceuticals (NASDAQ: REGN) is a growing biotech company that generates a ton of free cash flow. Over the years, it has obtained approval or authorization for 12 medicines. Its strong

Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (NASDAQ: CRSP) this year. The stock is up more than 60% in 2023 after the

Technology has been a dominant force in the stock market for the last two decades. Some of the world's most valuable companies, such as Nvidia, Meta Platforms, and Advanced Micro Devices, belong to

Drugmaker AbbVie (NYSE: ABBV) spun off from Abbott Laboratories (NYSE: ABT) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue

How much money does one need to start investing in stocks? $1 million? $10,000? The truth is, even a relatively modest sum of $100 is enough to get started for two reasons. First, nowadays, it isn't

Investing in stocks requires careful analysis of the potential risks and returns. One way to evaluate a stock is to consider how it fits into your portfolio. For example, do you want a stock that

December has been a big month for CRISPR Therapeutics (NASDAQ: CRSP). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment

"The thrill of victory and the agony of defeat."

That phrase became well-known years ago thanks to sportscaster Jim McKay. And it pretty much sums up the different trajectories for CRISPR

Vertex Pharmaceuticals (NASDAQ: VRTX) has brought in billions of dollars in earnings over time thanks to its leadership in the market for cystic fibrosis (CF) treatment. And along with partner

In late November, Roche's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next

Dividend stocks offer attractive features for income and growth investors alike. On the income side, many blue chip dividend stocks sport higher yields than those of risk-free assets such as the

Dividend income can boost your overall returns, and also provide you with some recurring cash flow for your portfolio. That's a good thing, because it means you don't have to sell your investments

When a company underperforms, the markets sometimes have a tendency to overreact. An earnings miss or a guidance cut can at times be enough to lead to a significant sell-off, even if the underlying

CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their

For the third day in a row, shares of big pharma bellwether Pfizer (NYSE: PFE) are heading higher -- which is kind of curious. Just last week, Pfizer issued downbeat guidance for the year ahead. But